Evidence map›Paper›PMID 33983080›Full record

ArticleJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2021

Global changes to the chemotherapy service during the covid-19 pandemic.

Man-Chie Chow, Pinkie Chambers, Georgina Singleton, Jignesh Patel, Silvie Cooper, Charlotte Mythen, Elysse Bautista-González, Georgia Chisnall, Nehla Djellouli, Benjamin Thwaites and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. A Comparative Analysis of COVID-19-Associated and Non-COVID-19-Associated MucormycosisEndocrine, metabolic & immune disorders drug targets · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Man-Chie ChowPharmacy Department, University College London Hospitals NHS Foundation Trust, UCLH-UCL Centre for Medicines Optimisation Research and Education, London, UK.ORCID https://orcid.org/0000-0003-0889-8946
Pinkie ChambersPharmacy Department, University College London Hospitals NHS Foundation Trust, UCLH-UCL Centre for Medicines Optimisation Research and Education, London, UK.ORCID https://orcid.org/0000-0002-6669-9411
Georgina SingletonDepartment for Targeted Intervention, UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine, University College London, London, UK.
Jignesh PatelRapid Research Evaluation and Appraisal Lab (RREAL), London, UK.
Silvie CooperDepartment of Applied Health Research, University College London, London, UK.
Charlotte MythenInstitute of Epidemiology and Healthcare, University College London, London, UK.
Elysse Bautista-GonzálezRapid Research Evaluation and Appraisal Lab (RREAL), London, UK.
Georgia ChisnallRapid Research Evaluation and Appraisal Lab (RREAL), London, UK.ORCID https://orcid.org/0000-0002-1524-4564
Nehla DjellouliUCL Institute for Global Health, London, UK.ORCID https://orcid.org/0000-0003-4200-2314
Benjamin ThwaitesPharmacy Department, University College London Hospitals NHS Foundation Trust, UCLH-UCL Centre for Medicines Optimisation Research and Education, London, UK.
Ian Ck WongPharmacy Department, University College London Hospitals NHS Foundation Trust, UCLH-UCL Centre for Medicines Optimisation Research and Education, London, UK.
Cecilia Vindrola-PadrosDepartment for Targeted Intervention, UCL/UCLH Surgical Outcomes Research Centre, Centre for Perioperative Medicine, University College London, London, UK.
University College London · GBUniversity College London Hospitals NHS Foundation Trust · GBRoyal College of Anaesthetists · GB

Funding

HSRD VA CDA 10-016
6 · The paper itself

Abstract

purposeIn response to the COVID-19 pandemic, changes to chemotherapy services were implemented as a means of managing imposed workload strains within health services and protecting patients from contracting COVID-19. Given the rapidly evolving nature of the pandemic many changes were rapidly adopted and were not substantiated by robust evidence. This study aimed to describe the changes adopted internationally to chemotherapy services, which may be used to guide future changes to treatment delivery.

methodsA survey was developed to understand the impact of COVID-19 on the delivery of systemic anti-cancer therapies (SACT). It comprised 22 questions and examined the strategies implemented during the pandemic to prioritise and protect patients receiving SACT and the participants' professional opinion of the strategies employed. The survey was available in English, Spanish and French and was distributed via professional bodies.

results129 responses were obtained from healthcare professionals working across 17 different countries. 45% of institutions had to implement treatment prioritisation strategies and all hospitals implemented changes in the delivery of treatment, including: reduction in treatments (69%), using less immunosuppressive agents (50%), allowing treatment breaks (14%) and switching to oral therapies (45%). Virtual clinic visits were perceived by participants as the most effective strategy to protect patients.

conclusionsThe pandemic has forced chemotherapy healthcare professionals to adopt new ways of working by reducing health interactions. Many areas of research are needed following this period, including understanding patients' perceptions of risks to treatment, utilisation of oral treatments and the impact of treatment breaks on cancer outcomes.

Indexed as

COVID-19Antineoplastic AgentsHealth PersonnelHumansNeoplasmsSurveys and QuestionnairesWorkloadAntineoplastic Agentsanti-cancer therapychemotherapycoronavirusCovid-19healthcare

Identifiers

PMID33983080
PMCPMC8367193
OpenAlexW3162040680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.